Final report of a phase II trial of nimotuzumab in the treatment of refractory and relapsed high-grade gliomas in children and adolescents. (2009). Hematology Meeting Reports (formerly Haematologica Reports), 1(6). https://doi.org/10.4081/hmr.v1i6.675